New approach offers promise for long-term efficacy
by Kelly Lawman, Beth Israel Deaconess Medical Center
Blood-contacting implantable medical devices, such as stents, heart valves, ventricular assist devices, and extracorporeal support systems, as well as vascular grafts and access catheters, are used worldwide to improve patients’ lives. However, these devices are prone to failure due to the body’s responses at the blood-material interface; clots can form and inflammatory reactions can prevent the device from performing as indicated.
Stem cell-derived, glucose-stimulated, insulin-producing cells (SC-β) are protected inside capsules engineered to be invisible to the host immune system. Photo courtesy of Omid Veiseh and Andrew Bader/Anderson/Langer Laboratory, Koch Institute at MIT
Researchers experiment with single shot that slows rejection
A drug-secreting gel that holds back the immune system—developed to help treat diseases such as brain cancer, ulcerative colitis, and arthritis—has now been shown to slow hand transplant rejection, in rats, when delivered through a single shot. The success may yield a new
Cross-Harvard collaboration explores new possibilities for personalized medicine
Harvard scientists have merged stem cell and ‘organ-on-a-chip’ technologies to grow, for the first time, functioning human heart tissue carrying an inherited cardiovascular disease. The research appears to be a big step forward for personalized medicine, as it is working proof that
A group of Brigham and Women’s Hospital, and Harvard Stem Cell Institute researchers, and collaborators at MIT and Massachusetts General Hospital have found a way to use stem cells as drug delivery vehicles.
The researchers inserted modified strands of messenger RNA into connective tissue stem cells—called mesenchymal stem